Incyte Corporation INCY
Set alert
At close
Pre-market · Nov 3, 5:34 AM ET
- YTD
- +21.53%
- 1 year
- +18.18%
- Open
- 119.02
- Prev close
- 120.39
- Mkt cap
- 24.47B
- Vol
- 1.75M
- Avg vol
- 1.61M
- EPS
- 1.96
- P/E
- 61.24
- Div yield
- 0.00%
More statistics
- Low
- 118.25
- High
- 121.52
- Forward P/E
- 13.86
- Beta
- 0.78
- Short ratio
- 5.61
- Inst. own
- 103.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 9, 2027
- 50-d avg
- 120.49
- 200-d avg
- 108.06
- 1y target
- 130.92
1D chart
Events in this range
- Nov 2, 2026Rating: Bernstein · Market Perform → Market Perform
Signals (98)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | 3:55 PM | 14 hours ago |
| SMA: Bearish | 3:55 PM | 14 hours ago |
| MACD: Sell Signal | 3:55 PM | 14 hours ago |
| MACD: Buy Signal | 3:48 PM | 14 hours ago |
| SMA: Bullish | 3:45 PM | 14 hours ago |
| MACD: Sell Signal | 3:44 PM | 14 hours ago |
| SMA: Bearish | 3:43 PM | 14 hours ago |
| MACD: Buy Signal | 3:38 PM | 14 hours ago |
| SMA: Bullish | 3:36 PM | 14 hours ago |
| SMA: Bullish | 3:36 PM | 14 hours ago |
| SMA: Bearish | 3:35 PM | 14 hours ago |
| SMA: Bearish | 3:35 PM | 14 hours ago |
| SMA: Bullish | 3:32 PM | 14 hours ago |
| SMA: Bearish | 3:31 PM | 14 hours ago |
| MACD: Sell Signal | 3:26 PM | 15 hours ago |
| MACD: Buy Signal | 3:20 PM | 15 hours ago |
| SMA: Bullish | 3:14 PM | 15 hours ago |
| SMA: Bearish | 3:13 PM | 15 hours ago |
| RSI: Overbought | 3:01 PM | 15 hours ago |
| MACD: Sell Signal | 2:54 PM | 15 hours ago |
Newest 20 of 98.
Key statistics
- Market cap
- 24.47B
- Enterprise value
- 20.72B
- Trailing P/E
- 61.24
- Forward P/E
- 13.86
- PEG ratio
- 10.82
- Price / sales
- 4.07
- Price / book
- 4.34
- EPS (TTM)
- 1.96
- Beta
- 0.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 6.71%
- Revenue (TTM)
- 6.01B
- Revenue growth
- 14.00%
- Free cash flow
- 1.29B
- Total cash
- 3.85B
- Total debt
- 37.41M
- Return on equity
- 7.84%
- Shares outstanding
- 203.83M
- Short % of float
- 8.34%
- 50-day average
- 120.49
- 200-day average
- 108.06
Analyst view
Consensus: buy
- Target (low)
- 86.00
- Target (mean)
- 130.92
- Target (high)
- 157.00
- Strong buy2
- Buy11
- Hold14
- Sell1
- Strong sell0
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate 2.01.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Dec 30, 2026 | 1.87 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | -3.93 | -3.60 | +0.33 | +8.40% |
| Jul 28, 2026 | Jun 30, 2026 | 2.15 | 3.09 | +0.94 | +43.72% |
| Apr 28, 2026 | Mar 31, 2026 | 1.34 | 1.81 | +0.47 | +35.07% |
| Feb 10, 2026 | Dec 31, 2025 | 1.90 | 1.80 | -0.10 | -5.26% |
| Oct 28, 2025 | Sep 30, 2025 | 1.66 | 2.26 | +0.60 | +36.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Bernstein | main | Market Perform | Market Perform |
| Oct 30, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 30, 2026 | Barclays | main | Overweight | Overweight |
| Oct 30, 2026 | Evercore ISI Group | main | In-Line | In-Line |
| Oct 30, 2026 | Oppenheimer | up | Perform | Outperform |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- incyte.com
News
- Aware Super Pty Ltd as trustee of Aware Super Sells 13,693 Shares of Incyte Corporation $INCY
- Bernstein Maintains Market Perform on Incyte, Raises Price Target to $108
- Wells Fargo Maintains Equal-Weight on Incyte, Lowers Price Target to $127
- RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $117
- Barclays Maintains Overweight on Incyte, Raises Price Target to $143
- This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
- Evercore ISI Group Maintains In-Line on Incyte, Raises Price Target to $127
- Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
- Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
- Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Your note
Sign in to keep a note on INCY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 29, 2026 | 0 |
| BAKER BROTHERS LIFE SCIENCES L P | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Mar 30, 2025 | 0 |
| CAGNONI PABLO J | Officer | Sale | Oct 14, 2026 | 183,200 |
| HOPPENOT HERVE | Director | Sale | Nov 9, 2025 | 329,646 |
| ISSA MOHAMED KHAIRIE | Officer | Stock Award(Grant) | Jul 15, 2026 | 71,797 |
| IYENGAR VIJAY K | Officer | Sale | Jul 15, 2025 | 40,540 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 15.09% | 30,762,330 | 3.69B | Jun 29, 2026 |
| Blackrock Inc. | 8.85% | 18,032,718 | 2.16B | Jun 29, 2026 |
| Dodge & Cox Inc. | 5.87% | 11,957,326 | 1.44B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 5.41% | 11,024,289 | 1.32B | Jun 29, 2026 |
| State Street Corporation | 4.77% | 9,722,336 | 1.17B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.82% | 7,791,091 | 935.24M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.90% | 7,953,128 | 954.69M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.64% | 5,390,922 | 647.13M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.13% | 4,346,927 | 521.81M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.91% | 3,894,319 | 467.47M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.17% | 2,386,201 | 286.44M | Jul 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.11% | 2,269,019 | 272.37M | Sep 29, 2026 |